BioMarin's Q1 Loss Shrinks 79% Due to Higher Rare Disease Drug Sales

Ultra-rare disease fighting biotech BioMarin Pharmaceutical  (NASDAQ: BMRN  ) proved in its first-quarter results after the bell that there's certainly growth to be had in developing therapies that treat rare diseases. For the quarter, BioMarin reported a revenue jump of 18.5%, to $151.5 million, driven by product sale gains across the board.

The company's launch of Vimizim during the quarter netted $0.9 million in revenue, while Naglazyme (by far BioMarin's best-selling drug), Kuvan, Aldurazye, and Firdapse all delivered revenue gains of 15%, 20%, 8%, and 31%, respectively. Though small, even BioMarin's collaborative and royalty revenue soared to $2.5 million combined versus just $0.6 million in the prior-year period.

Operating expenses for the quarter increased nearly 11%, to $178 million, as selling, general, and administrative expenses rose 18%, tied mainly to the launch of Vimizim. Research and development expenses increased by 3%, as well.

On the heels of higher sales came a significantly smaller adjusted quarterly loss of just $1.7 million, or $0.01 per share, compared to a loss of $8 million, or $0.07 per share, in the year-ago quarter. BioMarin announced that it ended the quarter with $1.14 billion in cash and cash equivalents.

Looking forward, BioMarin left its previous revenue guidance of $650 million to $680 million unchanged; however, it did note that current sales trends would favor the upper end of its current projections. Furthermore, the company now believes that its R&D expensing of $500 million to $530 million, as well as adjusted loss of $100 million to $130 million, are trending toward the lower-end of its prior guidance.


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2940324, ~/Articles/ArticleHandler.aspx, 12/21/2014 8:33:09 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 1 day ago Sponsored by:
DOW 17,804.80 26.65 0.15%
S&P 500 2,070.65 9.42 0.46%
NASD 4,765.38 16.98 0.36%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

12/19/2014 4:00 PM
BMRN $93.84 Up +2.01 +2.19%
BioMarin Pharmaceu… CAPS Rating: ****

Advertisement